CLINICAL_TRIALS
trial_result
· 2017-03-29
Clinical Trial Update: Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]
Summary
Open-label long-term safety study of pirfenidone in idiopathic pulmonary fibrosis; results from a Phase 3 trial have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2017-03-29